Dual amylin and calcitonin receptor agonist treatment improves insulin sensitivity and increases muscle-specific glucose uptake independent of weight loss-Reference-Cited by-同舟云学术

Dual amylin and calcitonin receptor agonist treatment improves insulin sensitivity and increases muscle-specific glucose uptake independent of weight loss

Published:2023-08 Issue: Volume:164 Page:114969
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Larsen Anna Thorsø,Melander Simone A.,Sonne Nina,Bredtoft Emma,Al-Rubai Mays,Karsdal Morten A.,Henriksen Kim

Funder

Danmarks Grundforskningsfond

Innovationsfonden

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference51 articles.

1. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): A 56-Week, open-Label, randomized clinical trial;Ahmann;Diabetes Care,2018

2. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial;Ahrén;Lancet Diabetes Endocrinol.,2017

3. A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats;Andreassen;Am. J. Physiol. Endocrinol. Metab.,2014

4. KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats;Andreassen;Mol. Metab.,2021

5. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, mul;Aroda;Lancet Diabetes Endocrinol.,2017

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Isoquinoline small molecule ligands are agonists and probe-dependent allosteric modulators of the glucagon subfamily of GPCRs;Biochemical Pharmacology;2024-11

2. The enduring metabolic improvement of combining dual amylin and calcitonin receptor agonist and semaglutide treatments in a rat model of obesity and diabetes;American Journal of Physiology-Endocrinology and Metabolism;2024-08-01

3. Les dépôts amyloïdes dans les îlots de Langerhans, fonctions pathologiques et cibles thérapeutiques;Médecine des Maladies Métaboliques;2024-05

4. Are insulin sensitizers the new strategy to treat Type 1 diabetes? A long‐acting dual amylin and calcitonin receptor agonist improves insulin‐mediated glycaemic control and controls body weight;British Journal of Pharmacology;2024-02-20

5. The Insulin Sensitizer KBP-336 Prevents Diabetes-Induced Cognitive decline in ZDF Rats;The Journal of Prevention of Alzheimer's Disease;2024